Syndax Pharmaceuticals Inc (NASDAQ: SNDX) is 9.90% higher on its value in year-to-date trading and has touched a low of $11.22 and a high of $25.34 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The SNDX stock was last observed hovering at around $22.94 in the last trading session, with the day’s gains setting it 0.81%.
Currently trading at $23.75, the stock is 3.93% and 8.43% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.88 million and changing 3.53% at the moment leaves the stock 26.31% off its SMA200. SNDX registered -2.54% loss for a year compared to 6-month gain of 25.20%. The firm has a 50-day simple moving average (SMA 50) of $7.85 and a 200-day simple moving average (SMA200) of -$6.89.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 11.55% loss in the last 1 month and extending the period to 3 months gives it a 42.22%, and is -0.54% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.19% over the week and 4.60% over the month.
Syndax Pharmaceuticals Inc (SNDX) has around 184 employees, a market worth around $2.02B and $0.00M in sales. Distance from 52-week low is 111.77% and -6.27% from its 52-week high. The company has generated returns on investments over the last 12 months (-37.74%).
Syndax Pharmaceuticals Inc quarterly earnings per share for the current quarter are estimated at -$0.99.The EPS is expected to shrink by -25.61% this year
259 institutions hold shares in Syndax Pharmaceuticals Inc (SNDX), with institutional investors hold 107.40% of the company’s shares. The shares outstanding are 84.83M, and float is at 80.38M with Short Float at 10.70%. Institutions hold 106.62% of the Float.
The top institutional shareholder in the company is Wellington Management Group, LLP with over 7.44 million shares valued at $155.81 million. The investor’s holdings represent 10.71% of the SNDX Shares outstanding. As of Jun 29, 2023, the second largest holder is Blackrock Inc. with 4.99 million shares valued at $104.46 million to account for 7.18% of the shares outstanding. The other top investors are State Street Corporation which holds 4.15 million shares representing 5.98% and valued at over $86.94 million, while Frazier Life Sciences Management, L.P. holds 5.34% of the shares totaling 3.71 million with a market value of $77.63 million.
Syndax Pharmaceuticals Inc (SNDX) Insider Activity
The most recent transaction is an insider sale by Morrison Briggs, the company’s Director. SEC filings show that Morrison Briggs sold 52,855 shares of the company’s common stock on Aug 09 ’23 at a price of $18.27 per share for a total of $0.97 million. Following the sale, the insider now owns 17836.0 shares.
Syndax Pharmaceuticals Inc disclosed in a document filed with the SEC on Aug 02 ’23 that Meury William (Director) sold a total of 83,000 shares of the company’s common stock. The trade occurred on Aug 02 ’23 and was made at $20.46 per share for $1.7 million. Following the transaction, the insider now directly holds 48000.0 shares of the SNDX stock.
Still, SEC filings show that on Jul 10 ’23, Morrison Briggs (Director) disposed off 52,855 shares at an average price of $20.40 for $1.08 million. The insider now directly holds 17,836 shares of Syndax Pharmaceuticals Inc (SNDX).
